Exhalation of 131I after radioiodine therapy: Dosimetric considerations based on measurements in exhaled air

被引:1
|
作者
Sudbrock, F. [1 ]
Fischer, Th. [1 ]
Zimmermanns, B. [1 ]
Drzezga, A. [1 ]
Schomaecker, K. [1 ]
机构
[1] Univ Hosp Cologne, Dept Nucl Med, D-50924 Cologne, Germany
关键词
Radioiodine therapy; Exhalation of radioactivity; Dosimetry; RADIATION-EXPOSURE; THYROID-DISEASES; FAMILIES; HYPERTHYROIDISM; INHALATION;
D O I
10.1016/j.jenvrad.2016.06.024
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
It is well known that a considerable amount of radioiodine is exhaled after radioiodine therapy (RIT) leading to unwanted radiation exposure through inhalation for non-involved persons. This study focuses on the amount of exhalation in the breath-out air of RIT-patients and the dosimetric consequences. Furthermore, the correlation between radioiodine uptake and exhalation was investigated. The radioiodine species were collected in a filter system and quantified over time by measurements with a scintillation counter. The dosimetric implications were then studied for different exposure scenarios. Of the activity administered to the patient, approximately 10(-3)% (50-110 ppm) is exhaled. The radioiodine inhalation taking place following exhalation in the vicinity yields doses of up to 500 mu Sv (children, staying with the patient immediately after application and for the next 8 h). Three days after administration the doses are significantly reduced. This study lays emphasis on previous assumptions that exhalation depends on thyroid storage. Regardless of the type of thyroid disease, the predominant form exhaled is organic radioiodine. The amount of exhaled radioiodine is small but from the point of view of radiation protection, by no means negligible immediately after administration. Radiation doses received by incqrporation of exhaled radioiodine can easily exceed 100 mu Sv soon after administration of radioiodine. Three days after RIT the radioactivity can still be measured in the exhaled air but even at maximum, the annual doses lie far below 10 mu Sv and are thus comparatively low. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [1] Exhalation of 131I after radioiodine therapy: measurements in exhaled air
    Schomaecker, Klaus
    Sudbrock, Ferdinand
    Fischer, Thomas
    Dietlein, Markus
    Kobe, Carsten
    Gaidouk, Mark
    Schicha, Harald
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) : 2165 - 2172
  • [2] Exhalation of 131I after radioiodine therapy: measurements in exhaled air
    Klaus Schomäcker
    Ferdinand Sudbrock
    Thomas Fischer
    Markus Dietlein
    Carsten Kobe
    Mark Gaidouk
    Harald Schicha
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 2165 - 2172
  • [3] Influence of Glucocorticoid Therapy on intratherapeutic Biodistribution of 131I Radioiodine Therapy in Graves' Disease
    Halstenberg, Jorg
    Kranert, Wolfgang Tilman
    Korkusuz, Hudayi
    Mayer, Amelie
    Ackermann, Hanns
    Grunwald, Frank
    Happel, Christian
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (02): : 43 - 49
  • [4] Parathyroid gland function after radioiodine (131I) therapy for toxic and non-toxic goitre
    Szumowski, Piotr
    Abdelrazek, Saeid
    Mojsak, Malgorzata
    Rogowski, Franciszek
    Kociura-Sawicka, Agnieszka
    Mysliwiec, Janusz
    ENDOKRYNOLOGIA POLSKA, 2013, 64 (05) : 340 - 345
  • [5] Dosimetric methodology for 131I therapy for benign thyroid diseases
    Piron, B.
    Broggio, D.
    Bardies, M.
    Barrau, C.
    Kotzki, P. O.
    Boudousq, V
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2020, 44 (04): : 261 - 266
  • [6] Effects of drugs on the efficacy of radioiodine (131I) therapy in hyperthyroid patients
    Oszukowska, Lidia
    Knapska-Kucharska, Malgorzata
    Lewinski, Andrzej
    ARCHIVES OF MEDICAL SCIENCE, 2010, 6 (01) : 4 - 10
  • [7] 131I Radioiodine therapy in Graves' disease: Us et coutumes, controversies and guidelines
    Bardet, S.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2020, 44 (04): : 267 - 271
  • [8] Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
    Kobe, Carsten
    Eschner, Wolfgang
    Wild, Markus
    Rahlff, Ilka
    Sudbrock, Ferdinand
    Schmidt, Matthias
    Dietlein, Markus
    Schicha, Harald
    NUCLEAR MEDICINE COMMUNICATIONS, 2010, 31 (03) : 201 - 205
  • [9] Dosimetric approach to 131I ablation therapy for the differentiated thyroid cancer
    Gortan, Fatma Arzu
    Yuksel, Alptug Ozer
    Gulaldi, Nedim Cuneyt Murat
    Coskun, Nazim
    Akca, Ceren Deniz Kapulu
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2022, 25 (03) : 260 - 268
  • [10] Thyroid Cancer: Radiation Safety Precautions in 131I Therapy Based on Actual Biokinetic Measurements
    Liu, Bin
    Peng, Weiai
    Huang, Rui
    Tian, Rong
    Zeng, Yu
    Kuang, Anren
    RADIOLOGY, 2014, 273 (01) : 211 - 219